The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

(2013) Martin Ridderstråle et al.   Cardiovascular Diabetology

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

(2013) Arne Ring et al.   Cardiovascular Diabetology

Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers

(2013) Sreeraj Macha et al.   CLINICAL DRUG INVESTIGATION

Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

(2013) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Secular Changes in the Age-Specific Prevalence of Diabetes Among U.S. Adults: 1988–2010

(2013) Yiling J. Cheng et al.   DIABETES CARE

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Economic Costs of Diabetes in the U.S. in 2012

(2013)   DIABETES CARE

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

(2013) S. Macha et al.   DIABETES OBESITY & METABOLISM

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

(2013) Tim Heise et al.   Diabetes Therapy

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

(2012) Tobias Brand et al.   ADVANCES IN THERAPY

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

(2012) S. Macha et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

(2012) Akiko Sarashina et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

(2012) Sreeraj Macha et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Year in Diabetes 2012: The Diabetes Tsunami

(2012) R. Sherwin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

(2011) L. Thomas et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Drug- and non-drug-associated QT interval prolongation

(2010) Charlotte Van Noord et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM